Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Lassman AB, Sepulveda-Sanchez JM, Cloughesy T, Gil-Gil MJ, et al. Clin Cancer Res 2022 Mar 28. pii: 688116. doi: 10.1158/1078-0432.CCR-21-2664.

Read + Share

Amedeo Smart

Independent Medical Education

Lassman AB, Sepulveda-Sanchez JM, Cloughesy T, Gil-Gil MJ, et al. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res 2022 Mar 28. pii: 688116. doi: 10.1158/1078-0432.CCR-21-2664.
PMID: 35344029